Entera Bio Ltd. - Ordinary Shares (ENTX) analyst actions
Rating and price-target actions on ENTX in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the ENTX overview →
1 measured ENTX analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation | Press release | +0.35% | +0.00% |
Keep exploring
More ENTX: earnings → · SEC filings → · ENTX overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| AngioDynamics, Inc. (ANGO) | 218 | +0.33% | 54% |
| Anixa Biosciences, Inc. (ANIX) | 217 | 0.00% | 49% |
| Precipio, Inc. (PRPO) | 217 | +0.51% | 52% |
| Sensus Healthcare, Inc. (SRTS) | 217 | 0.00% | 49% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.